GLP-1
The GLP-1 Exit Strategy: What Happens After You Stop?
50-67% of weight returns after stopping GLP-1s. Here's the clinical data on weight regain, muscle loss, and the trial testing the exit.
clinical trials
retatrutide
Retatrutide: The Triple Agonist That Makes GLP-1s Look Basic
Eli Lilly's retatrutide achieved 28.7% weight loss and 76% knee pain reduction in Phase 3. Seven more readouts coming in 2026.
MOTS-c
MOTS-c and the July 23 Decision That Could End Compounding Access
MOTS-c is the only peptide with two human trials. One proved it worked — then the company dissolved. The second is running. July 23, the FDA decides compounding access.